WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317954
CAS#: 78964-85-9 (Tromethamine)
Description: Fosfomycin trometamine is an antibiotic produced by Streptomyces fradiae.
Hodoodo Cat#: H317954
Name: Fosfomycin Tromethamine
CAS#: 78964-85-9 (Tromethamine)
Chemical Formula: C7H18NO7P
Exact Mass: 0.00
Molecular Weight: 259.190
Elemental Analysis: C, 32.44; H, 7.00; N, 5.40; O, 43.21; P, 11.95
Related CAS #: 23155-02-4 (free acid) 26016-98-8 (calcium) 26016-99-9 (sodium) 78964-85-9 (Tromethamine)
Synonym: Fosfomycin Tromethamine; FOSFOMYCIN TROMETHAMINE; Fosfomycin tromethanol; Tromethamine-fosfomycin; Fosfomycin trometamol salt; Fosfomycin tromethamine [USAN]; Tromethamine, Fosfomycin; Phosphomycin; Phosphonomycin;
IUPAC/Chemical Name: [1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium;hydroxy-[(2R,3S)-3-methyloxiran-2-yl]phosphinate
InChi Key: QZJIMDIBFFHQDW-LMLSDSMGSA-N
InChi Code: InChI=1S/C4H11NO3.C3H7O4P/c5-4(1-6,2-7)3-8;1-2-3(7-2)8(4,5)6/h6-8H,1-3,5H2;2-3H,1H3,(H2,4,5,6)/t;2-,3+/m.0/s1
SMILES Code: C[C@H]1[C@H](O1)P(=O)(O)[O-].C(C(CO)(CO)[NH3+])O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 259.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A,
Larrosa N, Almirante B. Fosfomycin-tromethamine long-term oral therapy for
difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother.
2015 Dec 14. pii: AAC.02611-15. [Epub ahead of print] PubMed PMID: 26666924.
2: Khawaja AR, Khan FB, Dar TI, Bhat AH, Wani MS, Wazir BS. Fosfomycin
tromethamine. Antibiotic of choice in the female patient: A multicenter study.
Cent European J Urol. 2015;68(3):371-5. doi: 10.5173/ceju.2015.590. Epub 2015 Oct
15. PubMed PMID: 26568884; PubMed Central PMCID: PMC4643705.
3: Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T. In vitro activity of
fosfomycin tromethamine against extended spectrum beta-lactamase producing
urinary tract bacteria. J Coll Physicians Surg Pak. 2014 Dec;24(12):914-7. doi:
12.2014/JCPSP.914917. PubMed PMID: 25523727.
4: Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi
BK, Yang WM, Zhao XK, Gao XF, Chen M. Evaluation of three-dose fosfomycin
tromethamine in the treatment of patients with urinary tract infections: an
uncontrolled, open-label, multicentre study. BMJ Open. 2013 Dec 4;3(12):e004157.
doi: 10.1136/bmjopen-2013-004157. PubMed PMID: 24309172; PubMed Central PMCID:
PMC3855495.
5: Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin
tromethamine against Gram-negative bacterial strains recovered from community-
and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013
Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3. PubMed
PMID: 23742831.
6: Knottnerus BJ, Nys S, Ter Riet G, Donker G, Geerlings SE, Stobberingh E.
Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated
urinary tract infections in adult female patients in The Netherlands? J
Antimicrob Chemother. 2008 Aug;62(2):356-9. doi: 10.1093/jac/dkn177. Epub 2008
Apr 19. PubMed PMID: 18424789.
7: Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F,
Bonello F, Ungheri D, Carlone NA. Role of fosfomycin tromethamine in modulating
non-specific defence mechanisms in chronic uremic patients towards ESBL-producing
Escherichia coli. Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):153-60. PubMed
PMID: 18336741.
8: Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G; Italian Medici
Medicina Generale (MMG) Group. Fosfomycin tromethamine in uncomplicated urinary
tract infections: a clinical study. Chemotherapy. 2005 May;51(2-3):162-6. Epub
2005 May 9. PubMed PMID: 15886477.
9: Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of
outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten
North American medical centres by three methods. J Antimicrob Chemother. 1999
Jan;43(1):137-40. PubMed PMID: 10381112.
10: Barry AL, Pfaller MA, Fuchs PC, Tenover FC, Reller LB, Allen SD, Hardy DJ,
Gerlach EH. Interpretive criteria and quality control parameters for determining
bacterial susceptibility to fosfomycin tromethamine. Eur J Clin Microbiol Infect
Dis. 1993 May;12(5):352-6. PubMed PMID: 8354302.
11: Cilli F, Pullukcu H, Aydemir S, Sipahi OR, Tasbakan M, Turhan A, Ulusoy S. In
vitro activity of fosfomycin tromethamine and linezolid against
vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents. 2008
Mar;31(3):297-8. doi: 10.1016/j.ijantimicag.2007.11.003. Epub 2008 Jan 3. PubMed
PMID: 18180144.
12: Aykut Arca E, Karabiber N. [Short communication: comparison of
susceptibilities of Escherichia coli urinary tract isolates against fosfomycin
tromethamine and different antibiotics]. Mikrobiyol Bul. 2007 Jan;41(1):115-9.
Turkish. PubMed PMID: 17427560.
13: Tempera G, Mirabile M, Mangiafico A, Caccamo M, Bonfiglio G. Fosfomycin
tromethamine in uncomplicated urinary tract infections: an epidemiological
survey. J Chemother. 2004 Apr;16(2):216-7. PubMed PMID: 15216960.
14: Stein GE. Fosfomycin tromethamine: single-dose treatment of acute cystitis.
Int J Fertil Womens Med. 1999 Mar-Apr;44(2):104-9. Review. PubMed PMID: 10338268.
15: Stein GE. Single-dose treatment of acute cystitis with fosfomycin
tromethamine. Ann Pharmacother. 1998 Feb;32(2):215-9. Review. PubMed PMID:
9496408.
16: Fuchs PC, Barry AL, Brown SD. Susceptibility testing quality control studies
with fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis. 1997
Jul;16(7):538-40. PubMed PMID: 9272392.
17: Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its
antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a
single-dose oral treatment for acute uncomplicated lower urinary tract
infections. Drugs. 1997 Apr;53(4):637-56. Review. PubMed PMID: 9098664.
18: Pfaller MA, Barry AL, Fuchs PC. Evaluation of disk susceptibility testing of
fosfomycin tromethamine. Diagn Microbiol Infect Dis. 1993 Jul;17(1):67-70. PubMed
PMID: 8359009.
19: Barry AL, Fuchs PC. In vitro susceptibility testing procedures for fosfomycin
tromethamine. Antimicrob Agents Chemother. 1991 Jun;35(6):1235-8. PubMed PMID:
1929270; PubMed Central PMCID: PMC284319.
